Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1832088 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL17887907 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL29709585 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL11059297 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL12904430 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL19127751 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL7148974 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL28773455 | 0.97 | PDE4A (0.48) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL4049818 | 0.92 | PDE4A (0.44) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL15841482 | 0.91 | TSHR (0.53) | TSHRPDE4ATP53CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10008749-B2 | Lithium ion battery | GM Global Technology Operations LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170365883-A1 | LITHIUM ION BATTERY | BAR ILAN UNIVERSITY (IL) | 2017-12-21 | — | — | US | disclosed |
| US-20170365882-A1 | LITHIUM ION BATTERY | GM Global Technology Operations LLC | 2017-12-21 | — | — | US | disclosed |
| US-9776945-B2 | Preparation and separation of a di-carboxylic acid-containing mixture | RENNOVIA INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776945-B2 | Preparation and separation of a di-carboxylic acid-containing mixture | RENNOVIA INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160090346-A1 | PREPARATION AND SEPARATION OF A DI-CARBOXYLIC ACID-CONTAINING MIXTURE | RENNOVIA INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090346-A1 | PREPARATION AND SEPARATION OF A DI-CARBOXYLIC ACID-CONTAINING MIXTURE | RENNOVIA INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | TSHR 1541/4885PDE4A 269/4885TP53 2980/4885 |
| US-20160090346-A1 | PREPARATION AND SEPARATION OF A DI-CARBOXYLIC ACID-CONTAINING MIXTURE | ALDOA, DERA, PGD | TSHR 4653/4885PDE4A 3857/4885TP53 1468/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | TSHR 1363/4885PDE4A 367/4885TP53 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.